Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00161668
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : March 15, 2007
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary:
This study is designed to assess the safety of Mylotarg therapy in routine practice.

Condition or disease Intervention/treatment
Acute Myeloid Leukemia Drug: Mylotarg

Layout table for study information
Study Type : Observational
Enrollment : 500 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Study Start Date : October 2001






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00161668


Locations
Show Show 59 study locations
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Layout table for investigator information
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00161668    
Other Study ID Numbers: 0903X-100847
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: March 15, 2007
Last Verified: March 2007
Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Gemtuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents